Published in PLoS One on April 22, 2010
Advanced vaccine candidates for Lassa fever. Viruses (2012) 0.90
Unusual patterns of IgG avidity in some young children following two doses of the adjuvanted pandemic H1N1 (2009) influenza virus vaccine. Clin Vaccine Immunol (2013) 0.89
Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity. Clin Vaccine Immunol (2012) 0.78
Low hemagglutinin antigen dose influenza vaccines adjuvanted with AS03 alter the long-term immune responses in BALB/c mice. Hum Vaccin Immunother (2016) 0.75
Generation of a More Immunogenic Measles Vaccine by Increasing Its Hemagglutinin Expression. J Virol (2016) 0.75
Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell (2000) 20.83
The alphaviruses: gene expression, replication, and evolution. Microbiol Rev (1994) 16.68
Propagation in tissue cultures of cytopathogenic agents from patients with measles. Proc Soc Exp Biol Med (1954) 9.02
A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (N Y) (1991) 7.08
Humoral immunity due to long-lived plasma cells. Immunity (1998) 6.35
Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med (2007) 6.13
Formaldehyde fixation. J Histochem Cytochem (1985) 5.89
Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol (2006) 5.22
Sindbis virus expression vectors: packaging of RNA replicons by using defective helper RNAs. J Virol (1993) 4.19
Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA (1967) 4.01
Measles antibody: reevaluation of protective titers. J Infect Dis (1990) 3.77
Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol (2009) 3.51
Extrafollicular antibody responses. Immunol Rev (2003) 3.45
Bone marrow is a major site of long-term antibody production after acute viral infection. J Virol (1995) 3.32
Importance of antibodies to the fusion glycoprotein of paramyxoviruses in the prevention of spread of infection. J Exp Med (1980) 3.32
Antibody avidity determination by ELISA using thiocyanate elution. J Immunol Methods (1986) 3.07
Aluminium compounds for use in vaccines. Immunol Cell Biol (2004) 2.99
Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J Pediatr (1977) 2.66
Differences in the appearance of antibodies to structural components of measles virus after immunization with inactivated and live virus. J Infect Dis (1975) 2.54
Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol (2008) 2.45
Global measles elimination. Nat Rev Microbiol (2006) 2.21
Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses. Cell Immunol (1989) 2.15
Vaccine adjuvants alter TCR-based selection thresholds. Immunity (2008) 2.10
How do adjuvants work? Important considerations for new generation adjuvants. Immunity (2007) 2.01
Germinal centre B cells: antigen specificity and changes in heavy chain class expression. Nature (1982) 1.89
Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med (2002) 1.88
Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA (1998) 1.83
A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med (2006) 1.82
Induction of long-lived germinal centers associated with persisting antigen after viral infection. J Exp Med (1996) 1.80
Identification of murine germinal center B cell subsets defined by the expression of surface isotypes and differentiation antigens. J Immunol (2000) 1.72
MEASLES IMMUNIZATION WITH KILLED VIRUS VACCINE. SERUM ANTIBODY TITERS AND EXPERIENCE WITH EXPOSURE TO MEASLES EPIDEMIC. Am J Dis Child (1965) 1.66
Antibody formation in mouse bone marrow. I. Evidence for the development of plaque-forming cells in situ. Immunology (1974) 1.65
Humoral immunity and long-lived plasma cells. Curr Opin Immunol (2002) 1.63
Measles virus infection in rhesus macaques: altered immune responses and comparison of the virulence of six different virus strains. J Infect Dis (1999) 1.62
An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol (2003) 1.56
The germinal center: a crucible for lymphocyte selection. Semin Immunol (1996) 1.56
Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein. J Virol (2000) 1.52
Development of attenuated measles-virus vaccines. A summary of recentinvestigation. Am J Dis Child (1962) 1.49
Mucosal and systemic adjuvant activity of alphavirus replicon particles. Proc Natl Acad Sci U S A (2006) 1.49
Alphavirus vectors and vaccination. Rev Med Virol (2002) 1.40
A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat Med (2003) 1.39
Altered reactivity to measles virus. Skin test reactivity and antibody response to measles virus antigens in recipients of killed measles virus vaccine. J Pediatr (1969) 1.38
Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors. Proc Natl Acad Sci U S A (1999) 1.38
Contribution of measles virus fusion protein in protective immunity: anti-F monoclonal antibodies neutralize virus infectivity and protect mice against challenge. J Virol (1990) 1.36
Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody. Nat Med (1999) 1.35
Adaptation of humoral memory. Immunol Rev (2006) 1.29
Serologic response of children to in-activated measles vaccine. JAMA (1962) 1.26
Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats. J Virol (2007) 1.24
Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life. J Infect Dis (2007) 1.22
The intrinsically disordered C-terminal domain of the measles virus nucleoprotein interacts with the C-terminal domain of the phosphoprotein via two distinct sites and remains predominantly unfolded. Protein Sci (2005) 1.20
Differential mortality by measles vaccine titer and sex. J Infect Dis (1993) 1.20
Development of antibody to measles virus polypeptides during complicated and uncomplicated measles virus infections. J Virol (1984) 1.20
Neutralizing B cell response in measles. Viral Immunol (2002) 1.17
Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles. Proc Natl Acad Sci U S A (2005) 1.16
Measles vaccines and the potential for worldwide eradication of measles. Pediatrics (2004) 1.16
Child mortality following standard, medium or high titre measles immunization in West Africa. Int J Epidemiol (1996) 1.12
Measles eradication: is it in our future? Am J Public Health (2000) 1.12
Altered reactivity to measles virus in previously vaccinated children. Can Med Assoc J (1970) 1.10
Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis. Vaccine (2007) 1.08
Immunodominant domains of the Measles virus hemagglutinin protein eliciting a neutralizing human B cell response. Arch Virol (2003) 1.08
Relative contributions of measles virus hemagglutinin- and fusion protein-specific serum antibodies to virus neutralization. J Virol (2005) 1.05
Atypical measles following immunization with killed measles vaccine. Can Med Assoc J (1970) 1.05
A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles. J Virol (2010) 0.99
Type I Interferons are essential for the efficacy of replicase-based DNA vaccines. Vaccine (2006) 0.99
Neonatal immunization with a Sindbis virus-DNA measles vaccine induces adult-like neutralizing antibodies and cell-mediated immunity in the presence of maternal antibodies. J Immunol (2006) 0.98
Class I-restricted CTL induction by mucosal immunization with naked DNA encoding measles virus haemagglutinin. J Gen Virol (1997) 0.98
An alphavirus replicon-based human metapneumovirus vaccine is immunogenic and protective in mice and cotton rats. J Virol (2008) 0.98
Atypical measles syndrome: a continuing problem. Am J Public Health (1979) 0.96
An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice. J Virol (2007) 0.95
A two-phase innate host response to alphavirus infection identified by mRNP-tagging in vivo. PLoS Pathog (2007) 0.95
The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines. Vaccine (2008) 0.92
Nonmucosal alphavirus vaccination stimulates a mucosal inductive environment in the peripheral draining lymph node. J Immunol (2008) 0.92
Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus. J Immunol (2002) 0.92
T cell responses in acute measles. Viral Immunol (2002) 0.90
Use of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virus. Clin Vaccine Immunol (2008) 0.89
Successful boosting of a DNA measles immunization with an oral plant-derived measles virus vaccine. J Virol (2002) 0.89
The development and evaluation of an attenuated measles virus vaccine. Am J Public Health Nations Health (1962) 0.88
Atypical measles in adolescents and young adults. Ann Intern Med (1979) 0.87
A chimeric alphavirus RNA replicon gene-based vaccine for human parainfluenza virus type 3 induces protective immunity against intranasal virus challenge. Vaccine (2006) 0.87
Atypical measles syndrome: pathologic and serologic findings. Pediatrics (1982) 0.86
Complement C3d conjugation to anthrax protective antigen promotes a rapid, sustained, and protective antibody response. PLoS One (2007) 0.86
Dose-dependent protection against or exacerbation of disease by a polylactide glycolide microparticle-adsorbed, alphavirus-based measles virus DNA vaccine in rhesus macaques. Clin Vaccine Immunol (2008) 0.86
Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins. J Virol (2005) 0.85
A novel intranasal Protollin-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice. Vaccine (2005) 0.85
Measles: old vaccines, new vaccines. Curr Top Microbiol Immunol (2009) 0.85
In vivo antibody response and in vitro CTL activation induced by selected measles vaccine candidates, prepared with purified Quil A components. Vaccine (2000) 0.85
Atypical measles. Severe illness in recipients of killed measles virus vaccine upon exposure to natural infection. JAMA (1972) 0.83
Establishment and characterisation of murine cells constitutively expressing the fusion, nucleoprotein and matrix proteins of measles virus. J Virol Methods (1993) 0.83
Enhanced MHC class II-restricted presentation of measles virus (MV) hemagglutinin in transgenic mice expressing human MV receptor CD46. Eur J Immunol (1998) 0.83
Intramolecular immunodominance and intermolecular selection of H2d-restricted peptides define the same immunodominant region of the measles virus fusion protein. Mol Immunol (1995) 0.82
Immunogenicity of peptides of measles virus origin and influence of adjuvants. Vaccine (2005) 0.81
Potency measurement of inactivated measles vaccines. Am J Dis Child (1962) 0.80
Differential activation of T cells by antibody-modulated processing of the flanking sequences of class II-restricted peptides. Int Immunol (1996) 0.79
Analysis of the requirements for class II-restricted T cell recognition of a single determinant reveals considerable diversity in the T cell response and degeneracy of peptide binding to I-Ed. J Immunol (1995) 0.76
Protective value of inactivated measles vaccine. Am J Dis Child (1962) 0.76
Roles of nonstructural protein nsP2 and Alpha/Beta interferons in determining the outcome of Sindbis virus infection. J Virol (2002) 2.55
Measles. Lancet (2011) 2.37
Global measles elimination. Nat Rev Microbiol (2006) 2.21
The influence of HIV-1 exposure and infection on levels of passively acquired antibodies to measles virus in Zambian infants. Clin Infect Dis (2007) 1.89
Luciferase imaging of a neurotropic viral infection in intact animals. J Virol (2003) 1.83
BAK alters neuronal excitability and can switch from anti- to pro-death function during postnatal development. Dev Cell (2003) 1.56
An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol (2003) 1.56
A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat Med (2003) 1.39
Immunogenicity of standard-titer measles vaccine in HIV-1-infected and uninfected Zambian children: an observational study. J Infect Dis (2007) 1.38
Suppression of human immunodeficiency virus replication during acute measles. J Infect Dis (2002) 1.31
Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein. J Virol (2004) 1.27
Survival from 9 months of age among HIV-infected and uninfected Zambian children prior to the availability of antiretroviral therapy. Clin Infect Dis (2008) 1.27
Gamma interferon-dependent, noncytolytic clearance of sindbis virus infection from neurons in vitro. J Virol (2005) 1.25
Class II fusion protein of alphaviruses drives membrane fusion through the same pathway as class I proteins. J Cell Biol (2005) 1.25
Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life. J Infect Dis (2007) 1.22
Synergistic roles of antibody and interferon in noncytolytic clearance of Sindbis virus from different regions of the central nervous system. J Virol (2007) 1.21
Measles vaccines. Front Biosci (2008) 1.19
Measles: immune suppression and immune responses. Int J Biochem Cell Biol (2004) 1.18
Differential regulation of interleukin (IL)-4, IL-5, and IL-10 during measles in Zambian children. J Infect Dis (2002) 1.18
Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum Gene Ther (2002) 1.17
HIV-1 infection in Zambian children impairs the development and avidity maturation of measles virus-specific immunoglobulin G after vaccination and infection. J Infect Dis (2009) 1.17
Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. J Neuroimmunol (2003) 1.16
Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles. Proc Natl Acad Sci U S A (2005) 1.16
Glutamate receptor antagonists protect from virus-induced neural degeneration. Ann Neurol (2004) 1.16
Protection from fatal viral encephalomyelitis: AMPA receptor antagonists have a direct effect on the inflammatory response to infection. Proc Natl Acad Sci U S A (2008) 1.15
Role for nsP2 proteins in the cessation of alphavirus minus-strand synthesis by host cells. J Virol (2006) 1.15
Role of CD8(+) lymphocytes in control and clearance of measles virus infection of rhesus monkeys. J Virol (2003) 1.15
Prospective study of measles in hospitalized, human immunodeficiency virus (HIV)-infected and HIV-uninfected children in Zambia. Clin Infect Dis (2002) 1.14
Gene expression patterns in dendritic cells infected with measles virus compared with other pathogens. Proc Natl Acad Sci U S A (2006) 1.12
Measles virus, immune control, and persistence. FEMS Microbiol Rev (2012) 1.12
Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Breast Cancer Res (2004) 1.10
Contribution of T cells to mortality in neurovirulent Sindbis virus encephalomyelitis. J Neuroimmunol (2002) 1.10
Noncytolytic clearance of sindbis virus infection from neurons by gamma interferon is dependent on Jak/STAT signaling. J Virol (2009) 1.09
Prolonged persistence of measles virus RNA is characteristic of primary infection dynamics. Proc Natl Acad Sci U S A (2012) 1.08
Limited contribution of humoral immunity to the clearance of measles viremia in rhesus monkeys. J Infect Dis (2004) 1.07
A single mutation in the E2 glycoprotein important for neurovirulence influences binding of sindbis virus to neuroblastoma cells. J Virol (2002) 1.07
The nsP3 macro domain is important for Sindbis virus replication in neurons and neurovirulence in mice. Virology (2009) 1.06
Functional and phenotypic changes in circulating lymphocytes from hospitalized zambian children with measles. Clin Diagn Lab Immunol (2002) 1.04
Characterization of immune responses elicited in macaques immunized sequentially with chimeric VEE/SIN alphavirus replicon particles expressing SIVGag and/or HIVEnv and with recombinant HIVgp140Env protein. AIDS Res Hum Retroviruses (2006) 1.01
Altered synthesis of interleukin-12 and type 1 and type 2 cytokinesin rhesus macaques during measles and atypical measles. J Infect Dis (2001) 1.00
Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins. J Virol (2005) 1.00
Immune-mediated clearance of virus from the central nervous system. Microbes Infect (2003) 1.00
In vitro suppression of human immunodeficiency virus type 1 replication by measles virus. J Virol (2005) 1.00
Characterization of human immunodeficiency virus Gag-specific gamma interferon-expressing cells following protective mucosal immunization with alphavirus replicon particles. J Virol (2005) 1.00
A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles. J Virol (2010) 0.99
Dynamic regulation of functionally distinct virus-specific T cells. Proc Natl Acad Sci U S A (2010) 0.99
BCL-2 and BAX protect adult mice from lethal Sindbis virus infection but do not protect spinal cord motor neurons or prevent paralysis. J Virol (2002) 0.99
Neonatal immunization with a Sindbis virus-DNA measles vaccine induces adult-like neutralizing antibodies and cell-mediated immunity in the presence of maternal antibodies. J Immunol (2006) 0.98
Rapid activation of poly(ADP-ribose) polymerase contributes to Sindbis virus and staurosporine-induced apoptotic cell death. Virology (2002) 0.97
Extensive immune-mediated hippocampal damage in mice surviving infection with neuroadapted Sindbis virus. Virology (2003) 0.97
Characterization of an in vitro model of alphavirus infection of immature and mature neurons. J Virol (2005) 0.97
C5 modulates airway hyperreactivity and pulmonary eosinophilia during enhanced respiratory syncytial virus disease by decreasing C3a receptor expression. J Virol (2006) 0.96
Enhanced immunogenicity to Mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A. Infect Immun (2003) 0.95
Heparin-binding and patterns of virulence for two recombinant strains of Sindbis virus. Virology (2005) 0.95
Slow clearance of measles virus RNA after acute infection. J Clin Virol (2007) 0.95
HIV type 1 infection is a risk factor for mortality in hospitalized Zambian children with measles. Clin Infect Dis (2008) 0.95
Alphavirus-induced encephalomyelitis: antibody-secreting cells and viral clearance from the nervous system. J Virol (2011) 0.95
Role of N-linked glycosylation for sindbis virus infection and replication in vertebrate and invertebrate systems. J Virol (2009) 0.94
Hemagglutinin protein is a primary target of the measles virus-specific HLA-A2-restricted CD8+ T cell response during measles and after vaccination. J Infect Dis (2007) 0.93
Gene expression changes in peripheral blood mononuclear cells during measles virus infection. Clin Vaccine Immunol (2007) 0.92
Successful respiratory immunization with dry powder live-attenuated measles virus vaccine in rhesus macaques. Proc Natl Acad Sci U S A (2011) 0.91
Measles virus inhibits human immunodeficiency virus type 1 reverse transcription and replication by blocking cell-cycle progression of CD4+ T lymphocytes. J Gen Virol (2008) 0.91
Sprouty-2 regulates HIV-specific T cell polyfunctionality. J Clin Invest (2014) 0.90
Interaction of Sindbis virus non-structural protein 3 with poly(ADP-ribose) polymerase 1 in neuronal cells. J Gen Virol (2009) 0.90
Antibody responses against HIV in rhesus macaques following combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles. AIDS Res Hum Retroviruses (2006) 0.90
The effect of measles-mumps-rubella (MMR) immunization on the immune responses of previously immunized primary school children. Vaccine (2003) 0.89
Genotyping of measles virus in clinical specimens on the basis of oligonucleotide microarray hybridization patterns. J Clin Microbiol (2006) 0.89
Effect of host cell lipid metabolism on alphavirus replication, virion morphogenesis, and infectivity. Proc Natl Acad Sci U S A (2008) 0.89
Use of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virus. Clin Vaccine Immunol (2008) 0.89
Increased thymic output during acute measles virus infection. J Virol (2003) 0.88
CD4+ and CD8+ T-lymphocyte subsets in Zambian children. J Trop Pediatr (2004) 0.87
A chimeric alphavirus RNA replicon gene-based vaccine for human parainfluenza virus type 3 induces protective immunity against intranasal virus challenge. Vaccine (2006) 0.87
Immune containment and consequences of measles virus infection in healthy and immunocompromised individuals. Clin Vaccine Immunol (2006) 0.87
Recruitment and retention of B cells in the central nervous system in response to alphavirus encephalomyelitis. J Virol (2012) 0.87
Acid sphingomyelinase deficiency increases susceptibility to fatal alphavirus encephalomyelitis. J Virol (2006) 0.86
Dose-dependent protection against or exacerbation of disease by a polylactide glycolide microparticle-adsorbed, alphavirus-based measles virus DNA vaccine in rhesus macaques. Clin Vaccine Immunol (2008) 0.86
Functional characterization of the alphavirus TF protein. J Virol (2013) 0.86
Measles virus infection of rhesus macaques affects neutrophil expression of IL-12 and IL-10. Viral Immunol (2003) 0.86
A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates. Arch Virol (2013) 0.86
Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins. J Virol (2005) 0.85
Vaccination of rhesus macaques with a recombinant measles virus expressing interleukin-12 alters humoral and cellular immune responses. J Infect Dis (2003) 0.83
Induction of dendritic cell production of type I and type III interferons by wild-type and vaccine strains of measles virus: role of defective interfering RNAs. J Virol (2013) 0.83
Differential effects of priming with DNA vaccines encoding the hemagglutinin and/or fusion proteins on cytokine responses after measles virus challenge. J Infect Dis (2003) 0.83
Differential immune responses to primary measles-mumps-rubella vaccination in Israeli children. Clin Diagn Lab Immunol (2004) 0.82
HIV-1 infection as a risk factor for incomplete childhood immunization in Zambia. J Trop Pediatr (2006) 0.82
Development of an artificial-antigen-presenting-cell-based assay for the detection of low-frequency virus-specific CD8(+) T cells in whole blood, with application for measles virus. Clin Vaccine Immunol (2009) 0.82
Poor immune responses of newborn rhesus macaques to measles virus DNA vaccines expressing the hemagglutinin and fusion glycoproteins. Clin Vaccine Immunol (2012) 0.81
Lipidated dengue-2 envelope protein domain III independently stimulates long-lasting neutralizing antibodies and reduces the risk of antibody-dependent enhancement. PLoS Negl Trop Dis (2013) 0.81
Infectious diseases of the nervous system and their impact in developing countries. PLoS Pathog (2009) 0.80